Point of Care Diagnostics Market – Growth Factors Analysis, Share and Forecast

The Point of Care Diagnostics Market growth of the global Point of Care diagnostics market can be attributed to factors such as increasing prevalence of respiratory diseases (such as COVID-19 and influenza) across the globe, and improved access to point-of-care devices through online platforms are some of the other key factors likely to drive the long-term growth.

High prevalence of infectious diseases:

The POC tests can greatly improve the management of infectious diseases, especially in developing countries where access to timely medical care is a challenge and the healthcare infrastructure is antiquated and sparse. According to UNAIDS, around 20.6 million people were living with HIV in East and Southern Africa in 2018. In 2019, 20,000 new HIV cases were registered in the Middle East and North Africa (Source: UNAIDS Data 2020). In the Asia Pacific, an estimated 5.8 million people were suffering from HIV in 2019, led by India and China. According to UNAIDS, in 2019, approximately 2.1 million people in India were infected with HIV. The high prevalence of HIV is likely to boost the demand for point-of-care diagnostics, further accelerating the treatment of HIV infection.

Listed below are important statistics related to major infectious diseases in developing countries:

According to the WHO, India has the highest tuberculosis burden, with an estimated incidence of 2.64 million cases in 2020.|
In 2019, around 4.3 million new tuberculosis cases were reported in Southeast Asia, and 632,000 people died due to TB infections in this region (Source: WHO).
According to the National Influenza Policy 2017, around 10,000 deaths and 40,000 hospitalizations are caused due to influenza in South Africa each year.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=106829185

Point of Care & Rapid Diagnostics Market

The point of care diagnostics market includes major Tier I and II suppliers like the point-of-care diagnostics market are Roche Diagnostics (Switzerland), Abbott Laboratories (US), Siemens Healthineers (Germany), Becton, Dickinson and Company (US), Johnson & Johnson (US), Danaher Corporation (US), Chembio Diagnostics (US), Quidel Corporation. These suppliers have their manufacturing facilities spread across regions such as North America and Europe. COVID-19 has impacted their businesses as well. Demand for point of care diagnostics from key end-users has increased rapidly amidst the global COVID-19 pandemic. Industry experts believe that COVID-19 will have long erm increase in the growth for the point of care diagnostics market in 2020. Along with this, increase in prevalence of different types of infectious diseases, easy access of POC products through online platforms, and growing awaness about the low turnout time of diagnosis using rapid point of care test in turn will boost demnd for POC devices in the coming years.

Demand for glucose monitoring products for home use result in the segment occupying the high share of the point of care diagnostics market

Glucose monitoring products owes a good market share in point of care diagnostics market. The large share of this segment is attributed to factors such as the increase in the availability of glucose motioring devices increase in the prevalence of diabetes couples with growing collaborations among players for develop advance PoC deviceas and rapus shift towards the adoption of home helathacare products.

Asia Pacific likely to emerge as the fastest growing point of care diagnostics market, globally

Geographically, the emerging Asian countries, such as China, India, South Korea, Japan and Singapore, are offering high-growth opportunities for market players. The Asia Pacific point of care market is projected to grow at the highest CAGR of 18.8% from 2020 to 2025. initiatives by the government,rising awareness about selftesting products, and increase in collaborations among key players in the point-of-care diagnostics market in the region. increasing number of hospitals in India and China; and rapid expansion of healthcare infrastructures,and increase in thenumber of research centers are driving the growth of the APAC point of care diagnostics market.

Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=106829185

Prominent players in this market Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Becton Dickinson and Company (US), Abbott Laboratories (US), Quidel Diagnostics (US), and Chembio Diagnostics (US). Other prominent players operating in this market are EKF Diagnostics (UK), Trinity Biotech (Ireland), and Fluxergy (France).

July 20, 2022 1

Contract Research Organization Services Market – Developing Regions is Well-Positioned for Strong Growth in the Coming Years

The Contract Research Organization (CROs) Services Market is estimated to grow from USD 115.1 billion by 2027 from USD 68.3 billion in 2022, at a CAGR of 11.0 % during the forecast period.

Increasing investment in pharmaceutical R&D:

Most pharmaceutical, biopharmaceutical, and medical device companies continue to invest heavily in the development of novel drugs and devices. The pharmaceutical industry, in particular, is R&D-intensive. Pharmaceutical companies invest in R&D to deliver high-quality and innovative products to the market. Trends suggest that the top pharmaceutical companies are increasing their R&D efficiencies through heavy investments in R&D and through collaborative R&D efforts. According to the EvaluatePharma report, the global pharmaceutical R&D spending was valued at USD 137 billion in 2012; this increased to USD 212 billion in 2021 and is projected to reach USD 254 billion by 2026. As per the report, R&D spending is observed to be growing steadily at a CAGR of 4.2% from 2020 to 2026. This is expected to boost the outsourcing of research services by pharmaceutical companies, biotechnology companies, as well as research and academic organizations.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167410116

Contract Research Organization (CROs) Services Market

Growth in the drugs and biologics market despite the COVID-19 pandemic:

Despite the ongoing COVID-19 pandemic, 2020 has been the second-best year for the pharmaceutical industry in terms of the number of drugs approved by the US FDA. This year witnessed the authorization of 53 drugs—a number surpassed only in 2018 with 59 pharmaceutical agents. The 53 approvals in 2020 comprised 40 new chemical entities and 13 biologics. The approved biologics included 10 monoclonal antibodies, 2 antibody-drug conjugates, 3 peptides, and 2 oligonucleotides. The FDA has authorized 160 drugs in the last three years (2018–2020), compared to the approval of only 21 drugs in 2010. This growth in the number of approved products worldwide is attributed to the rising investments by biopharmaceutical companies to develop biologics and biosimilars. Currently, more than half of the drug candidates in the discovery stage are biologics, such as proteins, peptides, and monoclonal antibodies. Biologics are expected to contribute around half of the revenue generated by the top 100 pharmaceutical product sales in 2022.

The clinical research services subsegment accounted for the largest share of the type segment in the CRO services market in 2021.

Based on type, the Contract Research Organization Services Market is segmented into clinical research services, early-phase development services, laboratory services, consulting services, and data management services. The clinical research services segment accounted for the largest share of this market in 2021. The large share of this segment can primarily be attributed to factors such as the increasing R&D of new drugs and the high cost of clinical trials.

The oncology subsegment accounted for the largest share of the therapeutic area segment in the CRO services market in 2021.

Based on therapeutic area, the Contract Research Organization (CROs) Services Market is segmented into oncology, infectious diseases, neurology, vaccines, cardiovascular system (CVS) disorders, metabolic disorders/endocrinology, immunological disorders, respiratory disorders, psychiatry, dermatology, hematology, ophthalmology, gastrointestinal diseases, genitourinary & women’s health, and other therapeutic areas. The oncology segment accounted for the largest share of the global Contract Research Organization Services Market in 2021. The large share of this segment is primarily attributed to the increasing number of drug discovery activities for oncology and the rising prevalence of cancer worldwide.

Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=167410116

The Asia Pacific region is the fastest-growing region of the CRO services market in 2021.

Based on the region The global Contract Research Organization (CROs) Services Market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The market in the Asia Pacific is estimated to record the highest CAGR during the forecast period. This can be attributed to the fast-growing pharmaceutical industry in the region, favorable government policies, increasing number of pharmaceutical companies establishing their manufacturing facilities in the region, and the lower cost of clinical trials in the region.

Key players in the Contract Research Organization Services Market include IQVIA Inc. (US), Laboratory Corporation of America Holdings (US), PPD, Inc. (Now a part of Thermo Fisher Scientific Inc.) (US), ICON plc (Ireland), Syneos Health, Inc. (US), Parexel International Corporation (US), and Charles River Laboratories International Inc. (US)

Speak to Analyst:
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=167410116

July 18, 2022 1

Global Animal Genetics Market Size, and Growth Projection

Growth Factors Driving the Market: The growth of Animal Genetics Market is majorly attributed to the increasing consumption of animal-derived protein, growing global population & rapid urbanization, growing focus on identifying superior breeds, increased adoption of genetic services to prevent genetic diseases & business loss, and increased adoption of advanced genetic technologies. On the other hand, the shortage of skilled professionals in veterinary research is a key factor restraining market growth.

The global animal genetics market is projected to reach USD 7.7 billion by 2026 from USD 5.5 billion in 2021, at a CAGR of 7.1% during the forecast period.

Industry Segmentation in Detailed:

“The live animals segment accounted for the largest market share in 2020”

Among the product segment, the live animals segment accounted for the largest market share in 2020. The large share of this segment is attributed to the large demand for poultry meat and eggs in developed countries, and simultaneously increasing demand for the same in developing countries due to the growing population and rapid urbanization in these regions. Additionally, changing diet patterns and increasing disposable income also contribute to a shift towards increased consumption of animal protein.

In the live animals segment, poultry accounted for the largest market share during the forecast period. This can be attributed majorly to the strong demand for poultry and eggs in developed countries. Additionally, in developing countries, the growing population and rapid urbanization is contributing to the rising global demand for poultry.

“Poultry accounted for the largest market share in the live animals segment during the forecast period.”

In the live animals segment, poultry accounted for the largest market share during the forecast period. This can be attributed to the strong demand for poultry and eggs in developed countries. Additionally, due to the growing population and rapid urbanization in developed countries, the demand coming from these regions is also increasing significantly.

“semen accounted for the largest market share during the forecast period”

Under the segment of the genetic material, semen held the largest share, most of which came from bovine semen during the forecast period. Growth in this market is mainly driven by the increasing need for raising highly productive animals to meet the growing demand for meat and other animal-derived products.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=12462093

Leading Key Players Analysis:

The major players in the global animal genetics market are Neogen Corporation (US), Genus (UK), URUS (US), EW Group (Germany), Groupe Grimaud (France), CRV Holding (Netherlands), Topigs Norsvin (Netherlands), Zoetis (US), Envigo (US), Hendix Genetics (Netherlands), and Animal Genetics (US). Some other players in the market include VetGen (US), DanBred (Denmark), Tropical Bovine Genetics (India), Trans Ova Genetics (US), Inguran LLC dba ST Genetics (US), Semex Alliance (Canada), Genetic Veterinary Sciences (US), Cobb-Vantress (US), Milk Source (US), Eurogene AI Services (Ireland).

Geographical Trends in Detailed:

Europe dominates the Animal Genetics market during the forecast period.

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period. The high growth in this regional market can be attributed to the established livestock sector, growing porcine industry, increasing population and urbanization, rising per capita incomes and increasing per capita spending on animal care, and increasing awareness about technologically advanced animal genetic products and services in this region.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=12462093

July 13, 2022 2

Cell Culture Media Market – Research Provides In-Depth Detailed Analysis of Trends and Forecast

The growth is majorly driven by the rising R&D spending in pharmaceutical companies, emerging cell culture technologies for cell-based vaccines, increasing demand for monoclonal antibodies, growth in stem cell research, the launch of new cell culture media by market players, and the growing focus on personalized medicine. On the other hand, expensive cell biology research products and ethical concerns regarding cell biology research are expected to hinder the growth.

Emerging cell culture technologies for cell-based vaccines;

In the pharmaceutical industry, cell culture has become a prominent part of vaccine production. The cell culture technology has been used to produce vaccines for rotavirus, polio, smallpox, hepatitis, rubella, and chickenpox. Cell-based flu vaccines have also been approved for use in the US and many European countries.

Earlier, vaccines were manufactured by growing and harvesting viruses in chicken eggs, which was a time-consuming process. On the other hand, cell culture-based vaccine production is a far more efficient method. Its advantages over traditional manufacturing methods include a shortened lead-time and the capability to produce vaccines in larger quantities as per demand. Moreover, cell culture-based vaccines can be stored over a longer period. According to a study published by the CDC in the Journal of Infectious Diseases (June 2020), cell-based vaccines provided greater protection against flu-related hospitalizations than standard-dose egg-based vaccines among Medicare beneficiaries 65 years and older. For the 2020-2021 flu season, all four flu viruses used in Flucelvax Quadrivalent were cell-derived. Consequently, recent years have seen a surge in cell-based vaccines, resulting in efforts by prominent companies to capitalize on the opportunities provided. Seqirus, for example, has been active in this field.

In February 2020, Seqirus (a part of CSL Limited) received US FDA approval for AUDENZ, a cell-based Influenza A (H5N1) Monovalent Vaccine for individuals aged six months and older.
In January 2019, Seqirus received approval from the European Commission for its new cell-based seasonal influenza vaccine, FLUCELVAX TETRA.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=97468536

The global cell culture media market is projected to USD 10.3 billion by 2026 from USD 4.9 billion in 2021, at a CAGR of 16.0 % between 2021 and 2026.

Report Objectives:

To define, describe, and forecast the global cell culture media market based on type, application, end user, and region.
To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
To strategically analyze micro-markets with respect to individual growth trends, future prospects, and contributions to the overall cell culture media market
To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders

The serum-free media subsegment of the type segment dominated Cell Culture Media Market in 2020:

by type, is segmented into serum-free media, classical media & salts, stem cell culture media, specialty media, chemically defined media, and other cell culture media. In 2020, the serum-free media segment accounted for the largest share of the market. This can be attributed to the advantages of serum-free media over other types of media, including consistent performance, increased growth & productivity, better control over physiological responsiveness, and reduced risk of contamination by serum-borne adventitious agents in cell culture.

North America was the largest regional market for Cell Culture Media Market in 2020.

The global cell culture media market has been segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In 2020, North America accounted for the largest share of the cell culture media market, followed by Europe. The growing regulatory approvals for cell culture-based vaccines, growth in the biotechnology & pharmaceutical industries, higher investments in cell-based research, and strong government support are the key factors driving the growth of the cell culture media market in North America.

Key Market Players:

Key players in the Cell Culture Media Market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Sartorius AG (Germany), Corning Incorporated (US).

Request Sample Research Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=97468536

July 8, 2022 0

Industrial Centrifuge Market Research, Growth by Top Key Players, Trends, Application, and Forecast Analysis

According to the new market research report “Industrial Centrifuge Market by Type (Sediment, Clarifier, Decanter, Disc, Filter, Basket, Screen), Operation (Batch, Continuous), Design (Horizontal, Vertical), End User (Chemical, Power, Food, Wastewater, Pharmaceutical, Paper) and Region – Global Forecast to 2025″, published by MarketsandMarkets™, is projected to reach USD 9.0 billion by 2025 from USD 7.2 billion in 2020, at a CAGR of 4.4% between 2020 and 2025.

Opportunity: Growing demad for centrifuges in developing countries

Developing countries such as India, Malaysia, Indonesia, and China are witnessing rapid urbanization, with infrastructure improvements in several sectors, such as wastewater treatment, pharmaceutical & biotech industries, and food and beverage. The rapid economic growth in these countries has encouraged the establishment of various process industries, which in turn is expected to drive the demand for centrifugation equipment.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=59612221

The increasing demand for centrifuges in process industries and the rising need for wastewater management solutions are the major factors driving the growth of this market. However, the high cost of centrifuges is expected to restrain the market growth during the forecast period.

Sedimentation centrifuges to dominated the industrial centrifuge market in 2019

On the basis of type, the market is segmented into sedimentation centrifuges and filtering centrifuges. In 2019, the sedimentation centrifuge segment accounted for the largest share of the market. The wide range of industrial applications, the ability to achieve high speeds, increase in oil and gas explorations, and the rising need for wastewater treatment are the major factors contributing to the growth of this segment.

Clarifier segment accounted for the largest share of the sedimentation centrifuge market, by type, in 2019

On the basis of type, the sedimentation centrifuge market is segmented into clarifiers/thickeners, decanter centrifuges, disk stack centrifuges, hydrocyclones, and other sedimentation centrifuges. In 2019, the clarifier/thickener segment accounted for the largest share of the sedimentation centrifuges market. These centrifuges are used in a number of industries, including wastewater treatment, mining, power, beverages, food processing, pharmaceuticals and biotechnology, and chemicals.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=59612221

North America is the largest regional market for industrial centrifuge in 2019

In 2019, North America accounted for the largest share of the industrial centrifuge market, followed by Europe. The high demand for crude oil, a large number of shale oil and gas drilling activities, government initiatives to manage wastewater, flourishing food processing industry, technological advancements, and government support for the development of innovative centrifugation systems are the key factors driving the growth of the market in North America.

Prominent players in the industrial centrifuge market are ANDRITZ AG (Austria), Alfa Laval Corporate AB (Sweden), GEA Group AG (Germany), Mitsubishi Kakoki Kaisha, Ltd. (Japan), Thomas Broadbent & Sons (UK), FLSmidth & Co. A/S (Denmark), Schlumberger Limited (US), Ferrum AG (Switzerland), Flottweg SE (Germany), SIEBTECHNIK TEMA (Germany), HEINKEL Drying & Separation Group (Germany), Gruppo Pieralisi – MAIP S.p.A. (Italy), SPX Flow Inc. (US), HAUS Centrifuge Technologies (Turkey), Elgin Separation Solutions (US), Comi Polaris Systems, Inc. (US), Dedert Corporation (US), US Centrifuge Systems (US), B&P Littleford (US), and Pneumatic Scale Angelus (US).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=59612221

April 13, 2022 2

Major Insights on Single Use Assemblies Market – Global Growth Opportunities

According to the new market research report “Single-use Assemblies Market by Product (Bag Assembly, Filtration Assembly, Bottle Assembly, Mixing Assembly), Application (Filtration, Storage), Solution (Standard, Customized), End User (Pharmaceutical, Biopharma, CMOs, CROs) – Global Forecast to 2026″, published by MarketsandMarkets™, is projected to reach USD 6.3 billion by 2026 from USD 2.2 billion in 2021, at a CAGR of 23.3% during the forecast period.

Driver: Rapid implementation and low risk of cross-contamination;

A single-use solution has numerous advantages over traditional bioprocessing technologies, due to which the adoption of single-use assemblies is growing continuously. These include the faster implementation of single-use assembly components in the bioprocess cycle and a lower risk of cross-contamination. Single-use assemblies are ergonomically designed to hold integrated single-use flow paths for faster set-up and reduced space requirements. The product design is aimed to reduce the amount of time and cost related to preparation, set-up, testing, validation, and documentation. In addition, with the elimination of the Clean-In-Place (CIP) and Sterilization-In-Place (SIP) steps, the project lead time for the implementation of single-use production plants is reduced by at least eight months as compared to stainless-steel reactors and reusable assemblies. Owing to such advantages, single-use solutions enable faster batch turnaround and product change-over.

Product cross-contamination is a major concern in the biomanufacturing industry. The potential for cross-contamination occurs when the same process equipment is used repeatedly in the process cycle. Unwanted protein contamination, for example, may reduce production yields by requiring additional purification steps, or in the worst possible case, proteins that co-purify may result in potentially fatal treatments. Since the product flow path is discarded and replaced after each batch, the risk of product cross-contamination between batches is virtually eliminated with the use of single-use assembly components. Single-use component manufacturers also typically make and assemble products in cleanrooms to ensure that their products do not introduce harmful particulates and endotoxins into a bioprocess. Such advantages are driving the adoption of single-use assemblies among end users in the biopharmaceutical pharmaceutical industries.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=46226549

The growth of the market can primarily be attributed to the major advantages of single-use technologies as compared to traditional stainless-steel assemblies, such as rapid implementation and the low risk of cross-contamination. The increasing biopharmaceutical RD expenditure and growing biologics market are also driving the market growth.

The biopharmaceutical pharmaceutical companies segment accounted for the largest share of the end user segment in the single-use assemblies market in 2020.

On the basis of end users, segmented into biopharmaceutical pharmaceutical companies, contract research manufacturing organizations (CROs CMOs), and academic research institutes. In 2020, the biopharmaceutical pharmaceutical companies segment accounted for the largest share of the single use assemblies market. The demand for biopharmaceuticals among the geriatric population is increasing as the elderly are more prone to diseases/disorders, which are treated using biologics. This has resulted in the increased focus of biopharmaceutical companies on developing affordable biologics at lower costs. As single-use assemblies have wide applications in each stage of the production cycle, their adoption is increasing with the growth in the production of biologics and biosimilars.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=46226549

The standard solutions segment accounted for the largest share of the solutions segment in the single-use assemblies market in 2020.

Based on solution, segmented into standard solutions and customized solutions. In 2020, the standard solutions segment accounted for the largest share of the market. The adoption of standard solutions is high in the pharmaceutical biopharmaceutical industries due to the advantages these solutions offer, such as manufacturing process efficiency with reduced capital costs, improved flexibility with the use of pre-qualified components for building assemblies, reduced implementation time, and more flexibility with production planning.

Geographically; In 2020, the Asia Pacific region accounted for the fasted growing region of the Single use Assemblies Market. This can be attributed to the growing biopharmaceutical market and biopharmaceutical manufacturing capabilities in Asian countries, rising life science research activities, increasing investments by pharmaceutical biotechnology companies, and the growth of the contract RD sector.

Prominent players operating in the single-use assemblies market are Thermo Fisher Scientific, Inc. (US), Sartorius Stedim Biotech (France), Danaher Corporation (US), Merck KGaA (Germany), Avantor, Inc. (US), and Saint-Gobain (France).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=46226549

April 12, 2022 0

Back-end Revenue Cycle Management Market | Geographical Growth | Opportunities | Key Players

The report “Back-End Revenue Cycle Management Market by Product and Services (Claim Processing, Denial Management, Payment Integrity), Delivery Mode (On-Premise, Cloud Based), End-User (Payer, Provider (Inpatient, Outpatient)), and Region – Global Forecast to 2027″, is projected to reach USD 12.2 billion by 2027 from USD 8.6 billion in 2019, at a CAGR of 4.4%.

Growing importance of denials management;

To reduce costs and maximize profits, insurance companies are increasingly denying claims as well as coverage to patients being treated for chronic or persistent illnesses. This is putting an extra burden on healthcare providers to manage operating costs, and in turn is supporting the adoption of back-end revenue cycle management solutions (with a growing number of healthcare providers focusing on properly analyzing denied claims and appealing them).

Many healthcare providers across the globe still use manual and paper-oriented approaches to manage denials. This results in errors, delayed follow-ups, and miscommunication between healthcare providers and insurance companies. The use of back-end revenue cycle management solutions over manual and paper-oriented approaches can not only help healthcare providers overcome these issues but also help them save significant costs. As a result, the demand for back-end revenue cycle management solutions is expected to increase among end users during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=204439794

Back-end Revenue Cycle Management Market

Leading Key Players and Analysis:

Athenahealth (US), Cerner Corporation (US), Allscripts Healthcare Solutions, Inc. (US), eClinicalWorks (US), Optum, Inc. (US), McKesson Corporation (US), Conifer Health Solutions (US), GeBBs Healthcare Solutions (US), The SSI Group (US), GE Healthcare (US), nThrive (US), DST Systems (US), Cognizant Technology Solutions (US), and Quest Diagnostics (US) are the key players in the Back-End RCM Market.

Cerner has a strong foothold in the back-end revenue cycle management market. The company caters to the healthcare technology and financial management needs of its global customers. Cerner focuses on research and development activities, deploying products, and acquisitions to enhance its market presence. For instance, in the past three years, the company deployed more than 15 back-end revenue cycle management solutions across various hospitals, care centers, and medical centers. The acquisition of Siemens Health Services in January 2015 further strengthened its back-end revenue cycle management portfolio.

Geographical Analysis in Detailed?

The back-end revenue cycle management market is divided into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share in 2018 owing to factors such as growing HCIT investments in the region and the presence of regulatory mandates. North America is followed by Europe and Asia. The market in Asia is relatively nascent; however, it is projected to be the fastest-growing market during the forecast period.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=204439794

Industry Segmentation:

The Services segment to dominate the back-end revenue cycle management market.

By product & service, segmented into software and services. The services segment is expected to account for the largest share of the Back-End RCM Market in 2018. The large share of this segment can be attributed to the recurring nature of services such as training and development, installation, software upgrades, consulting, and maintenance. However, due to the need for periodic software upgrades, the software segment is expected to witness the highest growth during the forecast period.

The cloud-based systems to register the highest CAGR during the forecast period

On the basis of delivery mode, segmented into on-premise and cloud-based systems. The cloud-based segment is expected to register the highest CAGR of the back-end revenue cycle management market during the forecast period. Growth in this segment can be attributed to the comparatively lower capital expenses and operational costs incurred in this model, alongside its scalability, flexibility, and affordability.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=204439794

April 7, 2022 1

Orthodontic Supplies Market Growth and key Industry Players, Analysis and Forecast

According to the new market research report “Orthodontic Supplies Market by Product (Braces (Removable, Fixed), Brackets (Ligating, Lingual, Metal), Archwires (Ni-Ti, steel), Anchorage, Ligature(Elastomeric, wire), Patient(Adult, Children), Users(Hospitals, Clinics, OTC) – Global Forecast to 2026″, published by MarketsandMarkets™, the Orthodontic Products Market is projected to reach USD 8.3 billion by 2026 from USD 5.4 billion in 2021, at a CAGR of 9.1% during the forecast period.

Opportunity: Emerging markets in APAC and RoW;

Emerging markets such as China, India, Brazil, and Mexico are expected to offer significant growth opportunities for players in the orthodontic supplies market. Growth in these markets can be attributed to the presence of a large patient population, rising disposable incomes among the middle-class population, and the increasing focus of public and private organizations on increasing the awareness about orthodontic treatments and dental hygiene. To leverage the significant growth opportunities in emerging countries, players are increasingly focusing on undertaking strategic developments to increase their presence in these markets and tap a large number of customers.

Along with this, many players are focusing on strategic investments to develop end-to-end digital software solutions with 3D digital scanning, diagnostics, outcome visualization, treatment planning, custom appliances, and custom lab products. For instance, in September 2020, Light Force Orthodontics, a manufacturer of customizable 3D-printed bracket systems, raised USD 14 million from Series B round led by Tyche Partners with follow-on investment from Matrix Partners and AM Ventures.

This 3D printing technology helps to create customized braces for each patient. This plays a critical role in significantly reducing the number of visits to orthodontic clinics for the adjustment of braces. These developments are expected to provide a wide range of opportunities for players to capture a large customer base in the orthopedic supplies market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=236529189

The Increasing prevalence of malocclusion, rising emphasis on effective orthodontic treatment and t the initiatives undertaken by governments to increase the awareness about orthodontic treatments are fueling the demand for orthodontic supplies during the forecast period.

The orthodontic supplies market includes major Tier I and II suppliers of orthodontic products are 3M (US), Envista Holdings Corporation (US), Dentsply Sirona (US), Align Technology (US), American Orthodontics (US), Rocky Mountain Orthodontics (US), G&H Orthodontics (US), Dentaurum (Germany), TP Orthodontics (US), Great Lakes Dental Technologies (US), DB Orthodontics (UK), Morelli Orthodontics (Brazil), ClearCorrect (US), and Ultradent Products (US).

These suppliers have their manufacturing facilities spread across regions such as North America and Europe. COVID-19 has impacted their businesses as well. Due to the pandemic, the orthodontic supplies market experienced short-term negative growth, which can be attributed to a sharp reduction in access to hospital and dental clinics and the temporarily shutdown of orthodontic clinics.

Orthodontic practices around the globe are facing challenges amid the pandemic. The adoption of strict protocols outside and inside dental clinics, increasing usage of teleorthodontics in case of urgent appointments, and opting for minimal orthodontic treatment procedures by many orthodontic clinics are likely to have a positive impact on the market. Moreover, post lockdown, as dental practices reopen, it is expected that patient volumes are anticipated to rebound at a higher pace.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=236529189

Demand for invisible braces among the target population due to their aesthetic benefits drives the growth of removable braces

Removable braces offer advantages over traditional braces, including easy removal of braces, reduced risk of periodontal diseases & tooth decay, and enhanced comfort. Factors such as strong focus on product innovation by players and growing awareness about the benefits associated with removable braces and the growing demand for invisible braces among teens and adults due to their aesthetic benefits is augumenting the growth of removable braces.

Asia Pacific likely to emerge as the fastest growing orthodontic supplies market, globally

Geographically, the emerging Asian countries, such as China, India, Japan and Singapore, are offering high-growth opportunities for market players. The Asia Pacific point of care market is projected to grow at the highest CAGR of 10.8% from 2021 to 2026. Expansion of healthcare infrastructure and increase in disposable personal income, increase patient population with malocclusion and tooth decay are factors likely to support the growth of market in the region. Moreover, the growing focus toward aesthetics products among adults and emergence of small manufacturers in the market are driving the growth of the APAC orthodontic supplies market.

Prominent players in this market are 3M (US), Envista Holdings Corporation (US), Dentsply Sirona (US), Align Technology (US), Rocky Mountain Orthodontics (US), G&H Orthodontics (US), Dentaurum (Germany), TP Orthodontics (US), Great Lakes Dental Technologies (US), DB Orthodontics (UK), among others.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=236529189

April 6, 2022 0

2022 Global Biobanking Market Report- Opportunities in Future with Different Segments

According to the new market research report “Biobanking Market by Product and Service(Equipment, Consumables, Services, Software), Sample Type (Blood Products, Human Tissues, Cell Lines, Nucleic Acids), Application( Regenerative Medicine, Life Science, Clinical Research) – Global Forecast”, published by MarketsandMarkets™, the biobanking devices market is expected to reach USD 2.69 Billion by 2022 from USD 1.85 Billion in 2017, at a CAGR of 7.8%.

Regenerative medicine applications for biobanking market will drive the market;

The Biobanking Devices Market plays an integral role in advancing biomedical and translational research, through the collection and preservation of biological samples, such as blood, tissues, and nucleic acids, which are then made available for use in research to discover disease-relevant biomarkers; this is further used for diagnosis, prognosis, and predicting drug responses. Growth in the number of research activities in this segment forms a major driver for the market. The availability of government funding for regenerative medicine, stem cell therapeutics, and cell & gene therapy is supporting research activities in this segment. Apart from this, the increasing trend of cord blood banking will also aid growth of this market segment. Future prospects including advancements in orthopedic procedures with the use of stem cells are expected to further support market growth for regenerative medicine.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=594

The Factors driving the growth of this market include the increasing number of genomics research activities for studying diseases; advances in biobanking and the growing trend of conserving cord blood stem cells of newborns; government & private funding to support regenerative medicine research; and the growing need for cost-effective drug discovery and development.

The equipment segment is expected to dominate the biobanking devices market.

By product and service, the biobanking market is segmented into equipment, consumables, services, and software. The equipment segment is expected to dominate the global market in 2017. Rising number of biobanks and the increasing number of biospecimens are factors increasing the demand for biobanking equipment.

Blood products are estimated to command the largest biobanking devices market share.

The biobanking market is segmented by sample type into blood products, human tissues, nucleic acids, human waste products, cell lines, and biological fluids. In 2017, the blood products segment is expected to account for the largest share of the market, by sample type. Rising incidence of blood disorders and the increasing demand for various types of blood products across the globe are driving the growth of this segment.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=594

North America is expected to account for the largest share of the biobanking devices market.

Based on region, the biobanking market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW). North America is expected to dominate the market in 2017, this is attributed to factors like increasing research activities in regenerative medicine, cell and gene therapy; growing interest in personalized medicine and biomarker discovery; increasing number of biotechnology and pharmaceutical companies; and rising investments in genomics and proteomics research in the region as compared to other regions.

Key players in the biobanking market include Thermo Fisher Scientific Inc. (U.S.), Tecan Group Ltd. (Switzerland), Qiagen N.V. (Germany), Hamilton Company (U.S.), Brooks Automation (U.S.), TTP Labtech Ltd (U.K.), VWR Corporation (U.S.), Promega Corporation (U.S.), Worthington Industries [(Taylor Wharton, U.S.)], Chart Industries (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Micronic (Netherlands), LVL Technologies GmbH & Co. KG (Germany), Panasonic Healthcare Holdings Co. Ltd (Japan), Greiner Bio One [Greiner Holding AG, Austria)], Biokryo GmbH (Germany), Biobank AS (Norway), Biorep Technologies Inc. (U.S.), Cell & Co Bioservices (France), RUCDR infinite biologics (U.S.), Modul-Bio (France), CSols Ltd (U.K.), Ziath (U.K.), and LabVantage Solutions Inc. (U.S.).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=594

April 5, 2022 2

Emerging Countries like North America, Europe Are New Revenue Pockets for the Humanized Mouse Model Market

The Research Report on “Humanized Mouse and Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoesis, Oncology, Immunology & Infectious Diseases) & End User (Pharmaceutical & Biotechnology Companies, CRO)) – Global Forecast” published by MarketsandMarkets™.

The humanized mouse models market to grow from USD 73.9 million, to USD 128.9 million, at a CAGR of 9.9% during the forecast period.

The humanized rat models market is expected to reach USD 8.9 million, at a CAGR of 8.4% during the forecast period.

The Growth in Humanized Mouse and Rat Model Market can primarily be attributed to factors such as the growing demand of personalized medicine, continuous support in the form of investments and grants from the government and private sectors, increasing number of R&D activities in pharmaceutical and biotechnology companies, and the increasing number of research activities involving humanized models. Increasing production of monoclonal antibodies and rising demand for humanized rat models are expected to provide a wide range of growth opportunities for players in the market.

Opportunity: Increased production of monoclonal antibodies;

With personalized medicine gaining in importance, monoclonal antibodies (mAbs) showcase an enormous potential to treat a wide range of diseases. This is a positive indicator for market growth as mouse models are extensively used in the production of mAbs. Researchers have replaced few parts of mouse antibodies with human components; the final antibodies with a mixture of human and mouse components are known as chimeric antibodies. Some monoclonal antibodies are now entirely human as a larger portion of the human component is engrafted in the mouse antibody.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=131763955

The oncology segment commanded the largest share of the humanized rat models market

By application, Categorized into oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. Of all these application segments, oncology accounted for the largest share of the humanized mouse models market in 2017. The increasing research activities and growing funding from various governments to carry out research studies on cancer are the major factors driving the growth of this segment.

Cell-based humanized mouse models to grow at the highest CAGR during the forecast period

By type, Categorized into genetic and cell-based humanized mouse models. The cell-based humanized mouse models segment is expected to grow at the highest CAGR during the study period (2017–2022). The high growth of this segment can be attributed to the growing applications of cell-based humanized mouse models.

The cell-based humanized mouse models segment is further categorized into CD34, PBMC, and BLT humanized mouse models. In 2017, the CD34 models segment commanded the largest share of the cell-based humanized mouse models market and is expected to grow at the highest CAGR during the forecast period. CD34 mouse models are used as in vivo platforms for analyzing the safety and effectiveness of potential new drugs that can modulate the immune system. They are used for long-term studies in the fields of immuno-oncology, infectious disease, and graft versus host disease. Thus, the growing application areas of CD34 models are expected to trigger the demand for these models in the coming years.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955

Geographically; North America dominated the global humanized mouse models market. Growth in this regional segment can be attributed to the increasing monoclonal antibody production, preclinical activities by CROs and pharmaceutical R&D, continued and responsible use of animals ensured by animal care organizations, growing biomedical research in the US along with government support for the development of protein drugs, and growing stem cell research in Canada.

The major market players in the humanized mouse models market include The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Horizon Discovery Group plc (UK), genOway, S.A. (France), Charles River Laboratories (US), Harbour Antibodies BV (China), Hera BioLabs (US), Vitalstar Biotechnology Co., Ltd. (China), inGenious Targeting Laboratory (US), AXENIS S.A.S (France), Crown Bioscience, Inc. (US), Transgenic, Inc. (Japan), and Champions Oncology, Inc. (US). The major players in the humanized rat models market include Horizon Discovery Group plc (UK), Hera BioLabs (US), and Yecuris Corporation (US).

Taconic is the second most leading players in the global humanized mouse and rat model market. The company is a provider of cell based and genetically modified mice models and supporting services such as custom model generation, imaging studies, and surgical services. The firm also has other distribution networks in India, Japan, and Singapore. A broad distribution network and a wide range of humanized mouse strains position the firm as one of the major players in the global cell based and genetic humanized mouse model market.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=131763955

April 4, 2022 2